Chemoembolization of hepatocellular carcinoma

Douglas E. Ramsey, Lily Y. Kemagis, Michael C. Soulen, Jean Francois H Geschwind

Research output: Contribution to journalArticle

Abstract

Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). Chemoembolization involves delivery of some type of chemotherapy combined with some type of arterial embolization to destroy tumor cells. Whereas diffuse tumors may require lobar embolization, smaller tumors may be treated selectively. The goal of TACE is to cause tumor necrosis and control tumor growth while preserving as much functional liver tissue as possible. The ultimate purpose, however, is to prolong life. Several different TACE protocols have been developed, with no consensus as to the most effective techniques. The effect of TACE on patient survival remains unclear. Several nonrandomized studies have demonstrated a beneficial effect of TACE on survival. This result has not been confirmed with randomized trials. It is clear, however, that TACE is a palliative procedure that has been unable to provide a cure for HCC. When combined with other procedures such as percutaneous ethanol injection, TACE has been more successful at achieving survival rates matching those obtained after surgical resection in similar patient populations. Finally, TACE may also be useful as a neoadjuvant therapy by improving the outcomes of potentially curative therapies and as a bridge to liver transplantation.

Original languageEnglish (US)
JournalJournal of Vascular and Interventional Radiology
Volume13
Issue number9 II
StatePublished - Sep 1 2002

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Neoadjuvant Therapy
Survival
Liver Transplantation
Ethanol
Necrosis
Survival Rate
Drug Therapy
Injections
Liver
Therapeutics
Growth
Population

Keywords

  • Liver neoplasms, chemotherapeutic infusion
  • Liver neoplasms, therapeutic radiology

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Ramsey, D. E., Kemagis, L. Y., Soulen, M. C., & Geschwind, J. F. H. (2002). Chemoembolization of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology, 13(9 II).

Chemoembolization of hepatocellular carcinoma. / Ramsey, Douglas E.; Kemagis, Lily Y.; Soulen, Michael C.; Geschwind, Jean Francois H.

In: Journal of Vascular and Interventional Radiology, Vol. 13, No. 9 II, 01.09.2002.

Research output: Contribution to journalArticle

Ramsey, DE, Kemagis, LY, Soulen, MC & Geschwind, JFH 2002, 'Chemoembolization of hepatocellular carcinoma', Journal of Vascular and Interventional Radiology, vol. 13, no. 9 II.
Ramsey DE, Kemagis LY, Soulen MC, Geschwind JFH. Chemoembolization of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology. 2002 Sep 1;13(9 II).
Ramsey, Douglas E. ; Kemagis, Lily Y. ; Soulen, Michael C. ; Geschwind, Jean Francois H. / Chemoembolization of hepatocellular carcinoma. In: Journal of Vascular and Interventional Radiology. 2002 ; Vol. 13, No. 9 II.
@article{259ade9f76a34fa3899284e45d3333ea,
title = "Chemoembolization of hepatocellular carcinoma",
abstract = "Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). Chemoembolization involves delivery of some type of chemotherapy combined with some type of arterial embolization to destroy tumor cells. Whereas diffuse tumors may require lobar embolization, smaller tumors may be treated selectively. The goal of TACE is to cause tumor necrosis and control tumor growth while preserving as much functional liver tissue as possible. The ultimate purpose, however, is to prolong life. Several different TACE protocols have been developed, with no consensus as to the most effective techniques. The effect of TACE on patient survival remains unclear. Several nonrandomized studies have demonstrated a beneficial effect of TACE on survival. This result has not been confirmed with randomized trials. It is clear, however, that TACE is a palliative procedure that has been unable to provide a cure for HCC. When combined with other procedures such as percutaneous ethanol injection, TACE has been more successful at achieving survival rates matching those obtained after surgical resection in similar patient populations. Finally, TACE may also be useful as a neoadjuvant therapy by improving the outcomes of potentially curative therapies and as a bridge to liver transplantation.",
keywords = "Liver neoplasms, chemotherapeutic infusion, Liver neoplasms, therapeutic radiology",
author = "Ramsey, {Douglas E.} and Kemagis, {Lily Y.} and Soulen, {Michael C.} and Geschwind, {Jean Francois H}",
year = "2002",
month = "9",
day = "1",
language = "English (US)",
volume = "13",
journal = "Journal of Vascular and Interventional Radiology",
issn = "1051-0443",
publisher = "Elsevier Inc.",
number = "9 II",

}

TY - JOUR

T1 - Chemoembolization of hepatocellular carcinoma

AU - Ramsey, Douglas E.

AU - Kemagis, Lily Y.

AU - Soulen, Michael C.

AU - Geschwind, Jean Francois H

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). Chemoembolization involves delivery of some type of chemotherapy combined with some type of arterial embolization to destroy tumor cells. Whereas diffuse tumors may require lobar embolization, smaller tumors may be treated selectively. The goal of TACE is to cause tumor necrosis and control tumor growth while preserving as much functional liver tissue as possible. The ultimate purpose, however, is to prolong life. Several different TACE protocols have been developed, with no consensus as to the most effective techniques. The effect of TACE on patient survival remains unclear. Several nonrandomized studies have demonstrated a beneficial effect of TACE on survival. This result has not been confirmed with randomized trials. It is clear, however, that TACE is a palliative procedure that has been unable to provide a cure for HCC. When combined with other procedures such as percutaneous ethanol injection, TACE has been more successful at achieving survival rates matching those obtained after surgical resection in similar patient populations. Finally, TACE may also be useful as a neoadjuvant therapy by improving the outcomes of potentially curative therapies and as a bridge to liver transplantation.

AB - Transcatheter arterial chemoembolization (TACE) is the mainstay of treatment for patients with unresectable hepatocellular carcinoma (HCC). Chemoembolization involves delivery of some type of chemotherapy combined with some type of arterial embolization to destroy tumor cells. Whereas diffuse tumors may require lobar embolization, smaller tumors may be treated selectively. The goal of TACE is to cause tumor necrosis and control tumor growth while preserving as much functional liver tissue as possible. The ultimate purpose, however, is to prolong life. Several different TACE protocols have been developed, with no consensus as to the most effective techniques. The effect of TACE on patient survival remains unclear. Several nonrandomized studies have demonstrated a beneficial effect of TACE on survival. This result has not been confirmed with randomized trials. It is clear, however, that TACE is a palliative procedure that has been unable to provide a cure for HCC. When combined with other procedures such as percutaneous ethanol injection, TACE has been more successful at achieving survival rates matching those obtained after surgical resection in similar patient populations. Finally, TACE may also be useful as a neoadjuvant therapy by improving the outcomes of potentially curative therapies and as a bridge to liver transplantation.

KW - Liver neoplasms, chemotherapeutic infusion

KW - Liver neoplasms, therapeutic radiology

UR - http://www.scopus.com/inward/record.url?scp=0036741728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036741728&partnerID=8YFLogxK

M3 - Article

C2 - 12354839

AN - SCOPUS:0036741728

VL - 13

JO - Journal of Vascular and Interventional Radiology

JF - Journal of Vascular and Interventional Radiology

SN - 1051-0443

IS - 9 II

ER -